Literature DB >> 20514955

Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates.

C T Chong1, T W K Lew, P Kuperan, J J E Tan, H L Tan, T K Kwek.   

Abstract

We report our initial experience using Profilnine SD, a 3-Factor prothrombin complex concentrate (PCC) in combination with fresh frozen plasma and vitamin K in seven patients admitted to our neurointensive care unit with oral anticoagulation therapy-related intracranial haemorrhage over a six-month period, to achieve rapid normalisation of the international normalised ratio (INR) and allow surgical evacuation when indicated. Four patients presented with subdural haematomas while three had intracerebral haematomas. Six of seven patients had admission INR in the appropriate therapeutic range for oral anticoagulation therapy. The median dose of PCC administered was 28.5 IU/kg body weight (interquartile range 21.3 to 38.5 IU/kg). All four patients with subdural haematoma underwent surgical evacuation once INR was less than 1.5. Median time from computed tomography diagnosis to surgery was 275 minutes (range 102 to 420 minutes). The median time to INR normalisation post-PCC administration was shorter, at 85 minutes (range 50 to 420 minutes) for the four patients who survived, versus 10 hours (range 9 to 44 hours) in the three patients who died. Two of the three patients who died had haematoma increase, worsening midline shift and subfalcine herniation, leading to withdrawal of therapy. Prothrombin complex concentrates should be considered for use in the urgent reversal of INR in oral anticoagulation therapy-related intracranial haemorrhage, potentially halting haematoma expansion and expediting urgent neurosurgical intervention, although data from randomised controlled trials is still lacking. The literature supporting the use of PCC is reviewed and a protocolised emergent treatment algorithm is proposed, which may help achieve earlier consistent normalisation of the INR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514955     DOI: 10.1177/0310057X1003800310

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  7 in total

Review 1.  Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis.

Authors:  Harrison Faulkner; Shubham Chakankar; Marco Mammi; Jack Yu Tung Lo; Joanne Doucette; Nawaf Al-Otaibi; Judi Abboud; Andrew Le; Rania A Mekary; Adomas Bunevicius
Journal:  Neurosurg Rev       Date:  2020-10-03       Impact factor: 3.042

2.  3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.

Authors:  G Morgan Jones; Michael J Erdman; Keaton S Smetana; Kerry M Mohrien; Joseph E Vandigo; Lucas Elijovich
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

3.  Evaluation of a fixed, weight-based dose of 3-factor prothrombin complex concentrate without adjunctive plasma following warfarin-associated intracranial hemorrhage.

Authors:  Kerry M Mohrien; G Morgan Jones; Andrew B Boucher; Lucas Elijovich
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

Review 4.  The emergent reversal of coagulopathies encountered in neurosurgery and neurology: a technical note.

Authors:  Joshua Eric Medow; Matthew R Dierks; Eliot Williams; J Christopher Zacko
Journal:  Clin Med Res       Date:  2014-11-07

Review 5.  Anticoagulation-related intracranial hemorrhages.

Authors:  Manoj K Mittal; Alejandro A Rabinstein
Journal:  Curr Atheroscler Rep       Date:  2012-08       Impact factor: 5.113

6.  A review of the clinical utility of INR to monitor and guide administration of prothrombin complex concentrate to orally anticoagulated patients.

Authors:  Sacha Sølbeck; Sisse R Ostrowski; Pär I Johansson
Journal:  Thromb J       Date:  2012-04-30

7.  A Retrospective Comparison of 3-Factor Prothrombin Complex Concentrate Products for Warfarin Reversal.

Authors:  G Morgan Jones; Brandon Cave; Ryan Cook
Journal:  Neurohospitalist       Date:  2020-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.